Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells

References

• Nador P G, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645–656
   PubMed Web of Science ®Google Scholar
• Klepfish A, Sarid R, Shtalrid M, Shvidel L, Berrebi A, Schattner A. Primary effusion lymphoma (PEL) in HIV-negative patients – a distinct clinical entity. Leuk Lymphoma 2001; 41: 439–443
   PubMed Web of Science ®Google Scholar
• Drexler H G, Uphoff C C, Gaidano G, Carbone A. Lymphoma cell lines: in vitro models for the study of HHV-8 + primary effusion lymphomas (body cavity-based lymphomas). Leukemia 1998; 12: 1507–1517
   PubMed Web of Science ®Google Scholar
• Jones K D, Aoki Y, Chang Y, Moore P S, Yarchoan R, Tosato G. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1997; 94: 2871–2879
   Web of Science ®Google Scholar
• Aoki Y, Yarchoan R, Braun J, Iwamoto A, Tosato G. Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood 2000; 96: 1599–1601
   PubMed Web of Science ®Google Scholar
• Masood R, Zhang Y, Bond M W, et al. Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 1995; 85: 3423–3430
   PubMed Web of Science ®Google Scholar
• Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13–21
   PubMed Web of Science ®Google Scholar
• Ovaa H, Kessler B M, Rolen U, Galardy P J, Ploegh H L, Masucci M G. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 2004; 101: 2253–2258
   PubMed Web of Science ®Google Scholar
• Milano A, Iaffaioli R V, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer 2007; 43: 1125–1133
   PubMed Web of Science ®Google Scholar
• Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207–214
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A, Ahmed M, et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol 2008; 216: 483–494
   PubMed Web of Science ®Google Scholar
• Uddin S, Ahmed M, Bavi P, et al. Bortezomib (Velcade®) induces p27Kip1 expression through SKP2 degradation in colorectal cancer. Cancer Res 2008; 68: 3379–3388
   PubMed Web of Science ®Google Scholar
• Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110: 633–641
   PubMed Web of Science ®Google Scholar
• Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8: 3419–3426
   PubMed Web of Science ®Google Scholar
• Soligo D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001; 113: 126–135
   PubMed Web of Science ®Google Scholar
• Wente M N, Eibl G, Reber H A, Friess H, Büchler M W, Hines O J. The proteasome inhibitor MG-132 induces apoptosis in human pancreatic cancer cells. Oncol Rep 2005; 14: 1635–1638
   PubMed Web of Science ®Google Scholar
• Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001; 28: 613–619
   PubMed Web of Science ®Google Scholar
• Bauer J, Wekerle H, Lassmann H. Apoptosis in brain-specific autoimmune disease. Curr Opin Immunol 1995; 7: 839–843
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Witzig T E, Adjei A A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178–194
   PubMed Web of Science ®Google Scholar
• Ferri K F, Jacotot E, Blanco J, et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of mitochondria and caspases. J Exp Med 2000; 192: 1081–1092
   PubMed Web of Science ®Google Scholar
• Liu X, Kim C N, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
   PubMed Web of Science ®Google Scholar
• Hengartner M O. The biochemistry of apoptosis. Nature 2000; 407: 770–776
   PubMed Web of Science ®Google Scholar
• Slee E A, Keogh S A, Martin S J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 2000; 7: 556–565
   PubMed Web of Science ®Google Scholar
• Hussain A R, Al-Jomah N A, Siraj A K, et al. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007; 67: 3888–3897
   PubMed Web of Science ®Google Scholar
• Hussain A, Al-Rasheed M, Manogaran P S, et al. Curcumin induced apoptosis in acute T cell leukemia. Apoptosis 2006; 11: 245–254
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A R, Manogaran P S, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005; 24: 7022–7030
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A R, Siraj A K, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178–4186
   PubMed Web of Science ®Google Scholar
• Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004; 101: 147–152
   PubMed Web of Science ®Google Scholar
• Hussain A R, Ahmed M, Al-Jomah N A, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008; 7: 3318–3329
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A R, Al-Hussein K A, et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005; 11: 3102–3108
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A, Al-Hussein K, Platanias L C, Bhatia K G. Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004; 320: 932–938
   PubMed Web of Science ®Google Scholar
• Glotzer M, Murray A W, Kirschner M W. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349: 132–138
   PubMed Web of Science ®Google Scholar
• Levkau B, Koyama H, Raines E W, Thibault P, Meloche S. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998; 1: 553–563
   PubMed Web of Science ®Google Scholar
• Coulombe P, Rodier G, Bonneil E, Thibault P, Meloche S. N-terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome. Mol Cell Biol 2004; 24: 6140–6150
   PubMed Web of Science ®Google Scholar
• Pagano M, Tam S W, Theodoras A M, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682–685
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella V J, Sausville E A, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071–3076
   PubMed Web of Science ®Google Scholar
• Chen F, Harrison L E. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 2005; 17: 809–816
   PubMed Web of Science ®Google Scholar
• Nunez G, Benedict M A, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998; 24: 3237–3245
   Google Scholar
• Li H, Zhu H, Xu C J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481–490
   PubMed Web of Science ®Google Scholar
• Desagher S, Osen-Sand A, Nichols A, et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999; 144: 891–901
   PubMed Web of Science ®Google Scholar
• Nakayama K I, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369–381
   PubMed Web of Science ®Google Scholar
• Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13: 41–47
   PubMed Web of Science ®Google Scholar
• Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002; 161: 207–216
   PubMed Web of Science ®Google Scholar
• Finucane D M, Bossy-Wetzel E, Waterhouse N J, Cotter T G, Green D R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999; 274: 2225–2233
   PubMed Web of Science ®Google Scholar
• Jürgensmeier J M, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed J C. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998; 95: 4997–5002
   PubMed Web of Science ®Google Scholar
• Gogvadze V, Robertson J D, Zhivotovsky B, Orrenius S. Cytochrome c release occurs via Ca2+-dependent and Ca2+-independent mechanisms that are regulated by Bax. J Biol Chem 2001; 276: 19066–19071
   PubMed Web of Science ®Google Scholar
• Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549–11556
   PubMed Web of Science ®Google Scholar
• LaCasse E C, Baird S, Korneluk R G, MacKenzie A E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–3259
   PubMed Web of Science ®Google Scholar